2025.Dec.09

Corporate

OBI Pharma Presents Preclinical Results for Bispecific ADC OBI-201 at SABCS 2025

Highlighting OBI-201’s Antitumor Activity and Payload Delivery Performance Across Multiple Tumor Animal Models

HOMEWhat’s NewNewsOBI Pharma Presents Preclinical Results for Bispecific ADC OBI-201 at SABCS 2025

Back to List

This article is password protected.

To view the content, please enter your password in the field below

2025.Dec.05

OBI-902 Receives Consecutive FDA Orphan Drug Designation Indication Expanded to Gastric Cancer Including Gastroesophageal Junction Adenocarcinoma